CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
Cannabidiol 100 MG/ML [Epidiolex] +1 moredrug
Likely dose
Cannabidiol 100 MG/ML [Epidiolex]from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04982029
NCT04982029Phase 2Completed
CompareCT.gov

Cannabidiol on reward-and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder: A Double-blind, Placebo-controlled, Cross-over Trial

Brigham and Women's Hospital·interventional·Posted Jul 29, 2021·Updated Oct 5, 2023

In Brief

A Phase 2 clinical trial evaluating Cannabidiol 100 MG/ML [Epidiolex] and Placebo for Opioid-use Disorder. Completed, enrolled 15 participants across 2 sites.

Detailed Summary

The purpose of this study is to determine the impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder on buprenorphine or methadone treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpioid-use Disorder
CountriesUnited States
CollaboratorsHarvard Medical School (HMS and HSDM)

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedJul 29, 2021
Enrollment StartApr 14, 2022
Primary CompletionDec 2, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.9 years ago

Interventions

Cannabidiol 100 MG/ML [Epidiolex]drug

600mg

Placebodrug

Matching placebo